Intranasal Administration of Carbamazepine-loaded Carboxymethyl Chitosan Nanoparticles for Drug Delivery to the Brain

Overview

Journal Asian J Pharm Sci

Date 2020 Feb 28

PMID 32104380

Citations 50

Authors

Shanshan Liu

Shili Yang

Paul C Ho

Affiliations

Soon will be listed here.

Abstract

Epilepsy is considered as a common and diverse set of chronic neurological disorders and its symptoms can be controlled by antiepileptic drugs (AEDs). The presence of p-glycoprotein and multi-drug resistance transporters in the blood-brain barrier could prevent the entry of AEDs into the brain, causing drug resistant epilepsy. To overcome this problem, we propose using carboxymethyl chitosan nanoparticles as a carrier to deliver carbamazepine (CBZ) intra-nasally with the purpose to bypass the blood-brain barrier thus to enhance the brain drug concentration and the treatment efficacy. Results so far indicate that the developed CBZ-NPs have small particle size (218.76 ± 2.41 nm) with high drug loading (around 35%) and high entrapment efficiency (around 80%). The release profiles of CBZ from the NPs are in accordance with the Korsmeyer-peppas model. The results show that both encapsulation of CBZ in nanoparticles and the nasal route determined the enhancement of the drug bioavailability and brain targeting characteristics.

Citing Articles

Nose-to-Brain Delivery of Chitosan-Grafted Leciplexes for Promoting the Bioavailability and Antidepressant Efficacy of Mirtazapine: In Vitro Assessment and Animal Studies.

El Sisi A, Eissa E, Hassan A, Bekhet M, Abo El-Ela F, Roh E Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861109 PMC: 11768278. DOI: 10.3390/ph18010046.

Encapsulation of paclitaxel into date palm lipid droplets for enhanced brain cancer therapy.

Yousfan A, Moursel N, Hanano A Sci Rep. 2024; 14(1):32057.

PMID: 39738802 PMC: 11685383. DOI: 10.1038/s41598-024-83715-7.

A Comprehensive Overview of the Current Status and Advancements in Various Treatment Strategies against Epilepsy.

Waris A, Siraj M, Khan A, Lin J, Asim M, Alhumaydh F ACS Pharmacol Transl Sci. 2024; 7(12):3729-3757.

PMID: 39698272 PMC: 11650742. DOI: 10.1021/acsptsci.4c00494.

Chitosan-Based Nanoformulations: Preclinical Investigations, Theranostic Advancements, and Clinical Trial Prospects for Targeting Diverse Pathologies.

Yadav S, Singh A, N Palei N, Pathak P, Verma A, Yadav J AAPS PharmSciTech. 2024; 25(8):263.

PMID: 39500815 DOI: 10.1208/s12249-024-02948-x.

Exploring chitosan nanoparticles for enhanced therapy in neurological disorders: a comprehensive review.

Vahab S, K I A, M S, Kumar V Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39377924 DOI: 10.1007/s00210-024-03507-8.

References

Arumugam K, Subramanian G, Mallayasamy S, Averineni R, Reddy M, Udupa N . A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008; 58(3):287-97. DOI: 10.2478/v10007-008-0014-3. View

Serralheiro A, Alves G, Fortuna A, Falcao A . Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. Eur J Pharm Sci. 2014; 60:32-9. DOI: 10.1016/j.ejps.2014.04.019. View

Nair R, Kumar A, Priya V, Yadav C, Raju P . Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. Lipids Health Dis. 2012; 11:72. PMC: 3476998. DOI: 10.1186/1476-511X-11-72. View

Daneman R, Zhou L, Agalliu D, Cahoy J, Kaushal A, Barres B . The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One. 2010; 5(10):e13741. PMC: 2966423. DOI: 10.1371/journal.pone.0013741. View

Loscher W, Klitgaard H, Twyman R, Schmidt D . New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013; 12(10):757-76. DOI: 10.1038/nrd4126. View

Wu W, He Q, Jiang C . Magnetic iron oxide nanoparticles: synthesis and surface functionalization strategies. Nanoscale Res Lett. 2011; 3(11):397-415. PMC: 3244954. DOI: 10.1007/s11671-008-9174-9. View

van der Lubben I, Verhoef J, Borchard G, Junginger H . Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 2001; 14(3):201-7. DOI: 10.1016/s0928-0987(01)00172-5. View

Barakat N, Omar S, Ahmed A . Carbamazepine uptake into rat brain following intra-olfactory transport. J Pharm Pharmacol. 2006; 58(1):63-72. DOI: 10.1211/jpp.58.1.0008. View

Migliore M, Vyas T, Campbell R, Amiji M, Waszczak B . Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci. 2009; 99(4):1745-61. DOI: 10.1002/jps.21939. View

10.

Tolou-Ghamari Z, Zare M, Habibabadi J, Najafi M . A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013; 18(Suppl 1):S81-5. PMC: 3743329. View

11.

Jain A, Khar R, Ahmed F, Diwan P . Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm. 2008; 69(2):426-35. DOI: 10.1016/j.ejpb.2007.12.001. View

12.

Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D . Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol. 1995; 47(6):1189-96. View

13.

Gavini E, Hegge A, Rassu G, Sanna V, Testa C, Pirisino G . Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm. 2005; 307(1):9-15. DOI: 10.1016/j.ijpharm.2005.09.013. View

14.

Tang H, Zhang P, Kieft T, Ryan S, Baker S, Wiesmann W . Antibacterial action of a novel functionalized chitosan-arginine against Gram-negative bacteria. Acta Biomater. 2010; 6(7):2562-71. PMC: 2874111. DOI: 10.1016/j.actbio.2010.01.002. View

15.

Nishimura A, Honda N, Sugioka N, Takada K, Shibata N . Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures. Biol Pharm Bull. 2008; 31(12):2302-8. DOI: 10.1248/bpb.31.2302. View

16.

Alpar H, Somavarapu S, Atuah K, Bramwell V . Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2004; 57(3):411-30. DOI: 10.1016/j.addr.2004.09.004. View

17.

Kramlinger K, Phillips K, Post R . Rash complicating carbamazepine treatment. J Clin Psychopharmacol. 1994; 14(6):408-13. View

18.

Costantino H, Illum L, Brandt G, Johnson P, Quay S . Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007; 337(1-2):1-24. DOI: 10.1016/j.ijpharm.2007.03.025. View

19.

Jiang L, Gao L, Wang X, Tang L, Ma J . The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm. 2009; 36(3):323-36. DOI: 10.1080/03639040903170750. View

20.

Illum L . Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11(1):1-18. DOI: 10.1016/s0928-0987(00)00087-7. View